KT Godder, J Metha, KY Chiang, S Adams, F van Rhee, S Singhal, K Higgins-Smith, W O Neal, S DeRienzo and JP Henslee-Downey.
|
|
- Buddy Phillips
- 6 years ago
- Views:
Transcription
1 (2001) 28, Nature Publishing Group All rights reserved /01 $ Acute myeloid leukaemia Partially mismatched related donor bone marrow transplantation as salvage for patients with AML who failed autologous stem cell transplant KT Godder, J Metha, KY Chiang, S Adams, F van Rhee, S Singhal, K Higgins-Smith, W O Neal, S DeRienzo and JP Henslee-Downey Division of Transplantation Medicine, South Carolina Cancer Center Columbia, SC, USA Summary: Treatment options for patients who relapse are limited and the outcome is dismal. Between August 1993 and January 1999, 17 patients, median age 26 (4 44) years, underwent T cell depleted bone marrow transplant from partially mismatched related donors (PMRD), as a salvage for AML relapsing after an autograft. The median time from auto-transplant to relapse was 7 months (1.5 24) and the interval between transplants was 10 months (3 30). All patients had active leukemia at time of transplant. Donors were siblings (n 8), parents (n 2), daughters (n 4) and others (n 3), and 82% were 2 major HLA antigen mismatched with the recipient. The conditioning therapy included total body irradiation in 14 patients and was busulfan-based in three. Graft-versus-host disease (GVHD) prophylaxis consisted of partial T cell depletion along with posttransplant immunosuppression. Median day to engraftment was 16 days (12 20). Acute GVHD was seen in six patients, and chronic GVHD in four of 13 surviving beyond 100 days. Ten patients died of nonrelapse causes, at (median 77) days. Two patients relapsed at 3 and 4 months. Five patients (29%) are surviving leukemia-free months post transplant (median 68 months). A short interval between transplants was predictive of early relapse but not mortality. Age 18 and 2 organ toxicities were marginally predictive of better survival. We conclude that BMT from PMRD is a reasonable option for patients with refractory AML post autograft. (2001) 28, Keywords: BMT; mismatched related donor; second transplant; relapsed AML; autologous Autologous stem cell transplant (auto) has been shown to be effective and perhaps superior to chemotherapy in Correspondence: Dr K Godder, Pediatric Stem Cell Program, Department of Pediatrics, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Mail Code CDRCP, Portland, OR 97219, USA Received 4 October 2000; accepted 13 September 2001 patients with acute myelogenous leukemia (AML) in first, or subsequent remissions. 1 5 Patients who relapse after autograft, even if they achieve remission, which is usually of short duration, eventually succumb to their disease within a few months. 6 Those with good performance status have the option to receive either intensive therapy followed by a second auto, or an allogeneic (allo)-bone marrow transplant. Second auto-transplant is relatively well tolerated. However, the main problem remains the high relapse rate; 58% relapse at 3 years was reported in 18 patients from Spain. 7 Of the patients undergoing second transplant at The Royal Marsden Hospital, four of seven who received a second auto, and all three receiving syngeneic graft relapsed. 8 Allogeneic-transplant from a matched sibling donor (MSD) is an option available to some patients, but most do not have a donor and are candidates for alternative donor transplant. No prospective study today compares first or second auto to alternative donor transplant. In a large matched pair analysis of patients undergoing first transplant, Ringden found no survival benefit for those who received alternative donor compared to auto. 9 In the current study, we report on the use of partially mismatched related donor (PMRD) bone marrow transplant (BMT) to salvage patients with AML who relapsed following autologous stem cell transplant and did not have a MSD. We show no engraftment failure and an acceptable incidence of graftversus-host disease (GVHD). We further discuss factors that may affect survival and relapse. This report is an update on an earlier publication. 10 Patients, donors and methods Patients Between August 1993 and January 1999, 17 consecutive patients who were referred to our center with AML, who relapsed following auto, underwent a T cell-depleted BMT from PMRD. Patients ages were 7 44 years (median 26) and their other characteristics are listed in Table 1. FAB morphology was M0 in three patients, M in four, M2 in one, M4 in eight and M5 in one. Median time to relapse post auto-transplant was 7 months (2 24), and between auto and allo was 10 months (3 31). All patients had active dis-
2 1032 Table 1 Patients, donors and transplant information UPN Age Disease Auto to Auto Donor Donor s Sex Conditioning Outcome COD /Gender state relapse allo/bmt relation age MM regimen a (years) (months) (months) (years) 27 36/F 2nd rel res 7 10 half-sister 28 no A alive 28 6/M 2nd rel res 9 19 sister 8 yes A alive 40 13/M 1st rel 7 10 father 44 no A dead pul hem 97 21/M 1st rel untr 4 5 brother 26 no B alive /M 1st rel res 2 6 brother 28 no A dead relapse /M 3rd rel res 9 20 daughter 18 yes A dead acute GVHD /F 1st rel sen 3 9 mother 50 no B dead sec malig /F 1st rel res 6 9 daughter 9 no C dead viral inf /F 2nd rel res 9 16 uncle 45 yes B dead sepsis 254 9/F 2nd rel half-sister 17 no D alive /M 1st rel res daughter 10 yes D dead sepsis /F 4th rel unk daughter 21 no B dead fungal inf /F 2nd rel unk 2 3 sister 36 no B dead relapse /M 2nd rel res 8 10 brother 11 no B alive /M 2nd rel res 4 7 brother 24 no B dead fungal inf /M 1st rel res 4 6 brother 22 no B dead pul toxicity /M 1st rel sen brother 33 no B dead acute GVHD rel relapse; res resistant; sen sensitive; unk unknown; untr untreated; TBI total body irradiation; VP etoposide; ARAC cytosine arabinoside; Cytoxan cyclophosphamide; pul hem pulmonary hemorrhage; sec malig secondary malignancy; inf infection; A TBI, VP, ARA- C, cytoxan, steroids; B TBI, VP, ARAC, cytoxan, steroids, ATG; C busulfan, thiotepa, melphalan, steroids; D busulfan, thiotepa, cytoxan, steroids. ease at time of allo-transplant: eight in first relapse, and seven in second relapse, one in third and forth relapse each. Attempted induction in 16 patients did not result in remission. Donors Donors were readily available from within the family and included eight siblings, two half-siblings, two parents, four offspring (daughters) and one uncle (Table 1), their median age was 24 (8 50), and only four were sex mismatched with the recipient. Patient-donor pairs HLA antigens were mismatched in the donor (GVH) direction in one antigen (n 3), two antigen (n 9) or three antigens (n 5) and in the recipient (HVG) direction in three, 10 and four antigens, respectively. Treatment protocol After signing an informed consent form, five patients were treated on PRMH-protocol No which included TBI, etoposide, cytosine-arabinoside, cytoxan and steroids, as previously described. 11 Another nine patients were treated on a similar protocol (No ) that includes the addition of pre-transplant anti-thymocyte globulin (ATG). 12 The remaining three patients were treated with a busulfan-based protocol. 9 GVHD prophylaxis was similar for patients on all protocols, and consisted of partial T cell depletion of the graft combined with post-transplant immunosuppression using cyclosporine, methylprednisolone and a course of ATG T cell depletion employed the use of monoclonal antibody followed by rabbit complement, with either T10B9 (n 5) or OKT3 (Ortho Biotech, Raritan, NJ, USA) (n 12) as previously described. 14,15 Pre-emptive donor leukocyte infusion (DLI) was given to six patients. Statistical considerations Engraftment day was defined as the first of 3 consecutive days for which the WBC count exceeded 1000/mm 3. Engraftment and remission status were confirmed by histology, cytogenetic analysis and RFLP (or VNTR) evaluation. GVHD was graded using Glucksberg s criteria and toxicity followed Bearman criteria. Patients were evaluated for engraftment and GVHD analysis if they survived beyond day 17 post transplant, the median day for engraftment on those protocols. Only patients who survived beyond day 28 were evaluated for relapse. All patients were eligible for survival analysis. Kaplan Meier estimates were used for survival and leukemia-free survival (LFS) analysis, and to assess the impact of various prognostic factors on survival and relapse. The Cox proportional hazard model was used for multivariate analysis. Cumulative incidence was used for assessment of GVHD, relapse and nonrelapse mortality. Results Bone marrow grafts Patients were infused with a median of ( ) nucleated cells/kg, containing ( ) T cells/kg recipient. The median CD34 dose (available in seven patients) was ( ) cells/kg. Four patients received pre-emptive donor leukocyte infusion at a median of 54 days post transplant ( 28 to 95). Cells were given in one to three infusions, and median total CD3 cell/kg for patient was ( ).
3 Engraftment All 14 patients who survived beyond the second week of transplant, achieved engraftment. The median time to WBC of 500/mm 3 and 1000/mm 3 was 16 (12 20) days. None of the patients experienced late graft failure. Regimen-related toxicity (RRT) Severe RRT (grade 3 4) of the pulmonary system occurred in three patients, kidney in nine patients (none required hemodialysis), liver in nine patients and cardiovascular system in 11 patients. The cardiovascular toxicity manifested as hypertension, secondary to cyclosporine and methylprednisolone used for GVHD prophylaxis. Veno-occlusive disease (VOD) developed in six patients, but was severe in only one patient. Despite the high toxicity, most patients recovered without long-term sequelae. Graft-versus-host disease Acute GVHD (agvhd) grade 1 developed in two patients, grade 2 in two patients, and grade 3 in one patient (Figure 1). Chronic GVHD (cgvhd) was seen in four of 13 patients surviving beyond day 100, and was graded as limited cgvhd in three. Severe and lethal GVHD developed only in patients who received DLI: two of six patients who received pre-emptive DLI succumbed to GVHD (on days 49 and 95, respectively). Relapse Only two patients relapsed, at 3 and 4 months following allo-transplant. Time to relapse post auto-transplant of 3 months was predictive of post-allo relapse; half of the patients who relapsed within 3 months post auto, but none of those who relapsed later, relapsed post allo (P 0.056). Relapse beyond 6 months, disease sensitivity, and patient s stage of disease (1st vs 1st relapse) were not predictive of relapse post allo-transplant (P 0.669, 0.123, 0.515, respectively). Leukemia-free survival (LFS) and survival Five patients are alive and disease free at a median of 57 months (30 73) post BMT, with good quality of life: Karnofsky/Lansky scores of 100 in four patients and 90 in one patient. They maintain longer remissions than following their auto-transplant, with a 29% Kaplan Meier estimate of survival (Figure 2). One patient who developed Hodgkin s disease 5 years after transplant, was treated with chemotherapy and bone marrow boost, and is now diseasefree 16 months after completion of therapy. Ten patients died of non-relapse causes (Table 1). The most common primary cause of death was infection: two patients died of early sepsis, two from fungal and one from viral infection. Factors affecting outcome Post-transplant toxicity ( 2 organs) and patient s age ( 18 years old) were the most significant (although marginal) factors in favor of long-term survival (P 0.09 and P 0.08, respectively in a univariate analysis). Time from autotransplant to relapse, auto to allo-transplant, antigen mismatch with the donor, donor s age, sex mismatch, disease sensitivity, conditioning protocol, T cell depletion agent, liver toxicity, VOD and GVHD were not shown to affect survival (Table 2). Multivariate analysis did not discriminate any factor to be significant in outcome. Discussion In this report we describe our experience with the use of PMRDs for BMT in AML patients who relapsed after autotransplant and did not have a MSD. To our knowledge, this is the largest study using PMRDs for those patients, employing a relatively uniform transplant regimen. Our study demonstrated a high rate of sustained engraftment, and acceptable incidence of GVHD; the cumulative incidence of grade 2 3 agvhd was only 18%, similar to patients who received PMRD as their first transplant, in our institution. 11,12 The Kaplan Meier estimate of LFS and overall survival at 3 years was 29% and with a good quality of life, despite all patients having active disease at time of transplant. Our low incidence of GVHD is especially significant in view of a recent report on the use of allo following autotransplant in lymphoma and AML. 16 This study reports a very high rate of GVHD and discourages the use of allo 1033 Cumulative incidence % Days Figure 1 Cumulative incidence of agvhd in AML patients who relapsed after autograft and were salvaged with PMRD-BMT. Probability Time (days) Figure 2 Probability of leukemia-free survival of AML patients who relapsed after autograft and were salvaged with PMRD-BMT.
4 1034 Table 2 Effect of risk factors on survival (using Kaplan Meier estimates of survival) Risk factor Surviving P value patients a Age at transplant (years) 18 3/ /13 Time to relapse (post auto) (months) 6 1/6 NS 6 4/11 Time between transplants (months) 6 1/4 NS 6 4/13 Disease sensitivity Sen 0/3 NS Res/unk 5/14 Antigen MM 3 3/11 NS 3 2/6 Donor s age (years) 20 3/6 NS 20 2/11 Donor patient sex-mismatch Yes 1/4 NS No 4/13 Conditioning therapy TBI 4/14 NS Non-TBI 1/3 Grade 3 4 toxicity b No. (organs) 2 3/ /13 Liver toxicity Yes 2/9 NS No 3/8 VOD Yes 0/ No 5/12 GvHD (grade 2) Yes 1/3 NS No 4/14 a Entries are number of patients surviving/number of patients. b Systems involved: pulmonary, gastrointestinal, central nervous system, cardiovascular, renal, hepatic. post auto altogether. In this series, 15 patients out of 20 who received allo underwent MSD-BMT. Eighty percent of those developed grade 2 4 GVHD. Five of the six patients with AML (four underwent MSD, one MUD and one PMRD) developed grade 3 4 GVHD. Our relatively low incidence of agvhd can be explained by the aggressive prevention methods including partial T cell depletion of the graft along with post-transplant immunosuppression. Mortality from GVHD in our cohort did not occur, except in patients who received pre-emptive DLI. One of them received DLI prior to day 100, during the time considered to be high risk for development of GVHD. Also, the cell dose was higher than 10 7 /kg, the level shown to be associated with increased risk of GVHD in PMRD-BMT patients. 17 The other patient developed GVHD and died of secondary CMV infection. In our study of allo following auto, we have not seen decreased relapse rates in patients who developed GVHD, 18,19 perhaps because of the small numbers of patients who developed GVHD or experienced relapse. The main cause of death in our study was non-relapse related. Data on patients undergoing a second allotransplant in general have shown 40 52% non-relapse mortality specifically due to VOD. We observed a relatively low incidence of VOD, perhaps as a result of using low molecular weight heparin for prophylaxis. On the other hand, the main cause of death in our series was infection, reflecting the prolonged time to immune reconstitution in patients who receive T cell-depleted alternative donor transplant. 22,23 Previously, we and others have also demonstrated an increased risk of transplant-related mortality if more than one organ with grade 3 4 toxicity was involved. 10,18,24 Unlike in second auto, and comparable to other second allo reports, 16,24 only two patients relapsed, with a cumulative incidence of relapse of 14%. Considering that this is a small series from a single institution, we refrain from inferring that the low relapse rate is significant. Nevertheless, these results suggest that the allogeneic effect of the grafted cells can be important in disease control, and justify its use in patients whose disease is refractory to chemotherapy. As expected, the interval between transplants did affect relapse but not survival. Patients whose allo was within 3 months of auto were more likely to relapse post allo. The Seattle and the Italian groups reporting on allo post auto did not show an impact of time between transplants using 1 year vs 1 year. 24,25 Others, (using the median 566 days vs 566, 18 or 6 vs 6 12 vs 12 months, 20 respectively) did demonstrate an effect on survival and relapse. The differences may be related to the diversity of diseases, disease states and time intervals. Considering the length of remission following auto-transplant, it was not significant in predicting outcome (relapse or survival) in our cohort. This is in contrast to patients who received a second auto (52% vs 20% P 0.02). 8 As to LFS and overall survival, although there are numerous reports on second transplant, only two series describe patients with AML who received allo post auto. The first is a multi-institutional trial reported by Tsai et al, 16 where only one of six AML patients survived, all dying from non-relapse causes. The second is a study from Seattle, reporting on 24 patients with AML, of whom 30% died of non-relapse mortality and 25% of relapsed disease, and 10 patients (46%) survived. 24 The difference between our and the Seattle group results, may be related to patient selection, as our patients were older and all of them were in relapse. Moreover, having an easily available donor may have biased our patients towards the sicker population, since those who were able to survive the waiting period for an unrelated donor search, as in the Seattle group, could have been the better risk patients. Patient age is the primary factor associated with survival in our and other studies. We showed that patients younger than 18 did marginally better than older patients. Those results were not significant in the multivariate analysis, perhaps because of sample size and its low power. Age has also been observed as an important factor in many other studies of second transplant, affecting mostly non-
5 transplant mortality. Mrsic et al, 20 studying second allotransplant, compared patients above and below the median age (26 years), and found similar results. Significantly improved outcome in young patients is related in part to their being devoid of other co-morbid conditions, but also, may be related to their faster immune reconstitution, and subsequent ability to fight infection. 23 As most patients do not have a MSD, using PMRDs is attractive, especially in refractory patients as these donors are easily accessible, and treatment can be initiated immediately. Most reports on second allo transplant show no survival benefit when using alternative donor 16,26 due to high regimen-related toxicity. The recent Seattle report, using alternative donors in 45 transplants and ours with 17 PMRDs suggest that with the advancement in support care, those transplants are more feasible. Another attractive approach to reducing toxicity is using non-myeloablative regimens. It is still to be determined whether patients with aggressive disease will benefit from this type of transplant. Moreover, difficulties in crossing HLA barriers may hamper those attempts in PMRD compared to those with MSD or MUD transplants. In summary, our study shows that PMRD-BMT is a reasonable option for patients with active AML who relapse post auto and do not have a MSD. The study also suggests that patients should not undergo allo within 3 months of their auto-transplant. As the relapse rate was low, our study proposes that improvement in support care, along with attempts to enhance immune reconstitution should improve overall survival in AML patients who relapsed post autotransplant and receive PMRD-BMT. References 1 Zittoun RA, Mandelli F, Willemze R et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. New Engl J Med 1995; 332: Miggiano MC, Gherlinzoni F, Rosti G et al. Autologous bone marrow transplantation in late first complete remission improves outcome in acute myelogenous leukemia. Leukemia 1996; 10: Cassileth PA, Andersen J, Lazarus HM et al. Autologous bone marrow transplant in acute myeloid leukemia in first remission. J Clin Oncol 1993; 11: Schiller GJ, Nimer SD, Territo MC et al. Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission. J Clin Oncol 1992; 10: Reiffers J, Gaspard MH, Maraninchi D et al. Comparison of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission: a prospective controlled trial. Br J Haematol 1989; 72: Keating MJ, Kantarjian H, Smith-TL et al. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol 1989; 7: De la Rubia J, Sanz GF, Martin G et al. Autologous bone marrow transplantation for patients with acute myeloblastic leukemia in relapse after autologous blood stem cell transplantation. Bone Marrow Transplant 1996; 18: Mehta J, Powles R, Treleaven J et al. Outcome of acute leukemia relapsing after bone marrow transplantation: utility of second transplants and adoptive immunotherapy. Bone Marrow Transplant 1997; 19: Ringden O, Labopin M, Gluckman E et al. Donor search or autografting in patients with acute leukemia who lack an HLA-identical sibling? A matched pair analysis. Bone Marrow Transplant 1997; 19: Godder K, Pati AR, Abhyankar S et al. Partially mismatched related donor transplants as salvage therapy for patients with refractory leukemia who relapse post-bmt. Bone Marrow Transplant 1996; 17: Henslee-Downey PJ, Abhyankar SH, Parrish RS et al. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood 1997; 89: Henslee-Downey PJ, Lee CG, LJ Hazlett et al. Rare failure to engraft following haploidentical T-cell depleted marrow transplantation using enhanced host immunoablation and OKT3 graft purging. Exp Hematol 1997; 25: Abstr Godder KT, Hazlett LJ, Abhyankar SH et al. Partially mismatched related donors allow for early allogeneic transplant intervention and improved disease free survival in young patients with poor prognosis acute leukemia J Clin Oncol 2000: 18: Lee C, Brouillette M, Lamb L et al. Use of a closed system for V -positive T-cell depletion of marrow for use in partially mismatched related donor transplantation. Prog Clin Biol Res 1994: 389: Lee C, Brouillette M, Hazlett L et al. Comparison of engraftment and acute GvHD following transplantation of partially mismatched grafts T cell depleted with OKT3 or T10B9 monoclonal antibody. J Hematother 1997; 4: Tsai T, Goodman S, Saez R et al. Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation. Bone Marrow Transplant 1997; 20: Pati AR, Godder K, Parrish R et al. Pre-emptive therapy with donor leukocyte infusions to prevent relapse following partially mismatched related donor bone marrow transplantation. Blood 1996; 88: 259a. 18 Radich JP, Sanders JE, Buckner CD et al. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. J Clin Oncol 1993; 11: Barrett AJ, Locatelli F, Treleaven JG et al. Second transplants for leukemic relapse after bone marrow transplantation: high early mortality but favorable effect of chronic GVHD on continued remission. Br J Haematol 1991; 79: Mrsic M, Horowitz MM, Atkinson K et al. Second HLAidentical sibling transplants for leukemia recurrence. Bone Marrow Transplant 1992; 9: Wagner JE, Vogelsang GB, Zehanbaur BA et al. Relapse of leukemia after bone marrow transplantation: effect of second myeloablative therapy. Bone Marrow Transplant 1992; 9: Lamb LS Jr, Gee AP, Henslee-Downey PJ et al. Phenotypic and functional reconstitution of peripheral blood lymphocytes following T cell-depleted bone marrow transplantation from partially mismatched related donors. Bone Marrow Transplant 1998; 21: Small TN, Papadopoulos EB, Boulad F et al. Comparison of immune reconstitution after related and related T-cell depleted bone marrow transplantation: effect of patient age and donor leukocyte infusion. Blood 1999; 93: Radich JP, Gooley T, Sanders J et al. Second allogeneic transplantation after failure of first autologous transplantation. Biol Blood Marrow Transplant 2000; 6:
6 Bosi A, Bacci S, Miniero R et al. Second allogeneic bone marrow transplantation in acute leukemia: a multicenter study from the Gruppo Italiano Trapianto Di Modollo Osseo (GITMO). Leukemia 1997; 11: Chiang KY, Weisdorf DJ, Davies SM et al. Outcome of second bone marrow transplantation following a uniform conditioning regimen as therapy for malignant relapse. Bone Marrow Transplant 1996; 17:
Acute leukemia Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients
(2004) 33, 389 396 & 2004 Nature Publishing Group All rights reserved 0268-3369/04 $25.00 www.nature.com/bmt Acute leukemia Bone marrow transplantation from partially HLA-mismatched family donors for acute
More information5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow
5/9/2018 or Stem Cell Harvest Where we are now, and What s Coming AA MDS International Foundation Indianapolis IN Luke Akard MD May 19, 2018 Infusion Transplant Conditioning Treatment 2-7 days STEM CELL
More informationWhat s a Transplant? What s not?
What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence
More informationReduced-intensity Conditioning Transplantation
Reduced-intensity Conditioning Transplantation Current Role and Future Prospect He Huang M.D., Ph.D. Bone Marrow Transplantation Center The First Affiliated Hospital Zhejiang University School of Medicine,
More informationIntensified conditioning regimen in bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia
Bone Marrow Transplantation, (1998) 22, 1029 1033 1998 Stockton Press All rights reserved 0268 3369/98 $12.00 http://www.stockton-press.co.uk/bmt Intensified conditioning regimen in bone marrow transplantation
More informationAIH, Marseille 30/09/06
ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOID MALIGNANCIES Transplant and Cellular Therapy Unit Institut Paoli Calmettes Inserm U599 Université de la Méditerranée ée Marseille, France AIH, Marseille
More informationRelapse Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant
(2004) 34, 721 727 & 2004 Nature Publishing Group All rights reserved 0268-3369/04 $30.00 www.nature.com/bmt Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling
More informationHLA-DR-matched Parental Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-risk Acute Leukemia
BRIEF COMMUNICATION HLA-DR-matched Parental Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-risk Acute Leukemia Shang-Ju Wu, Ming Yao,* Jih-Luh Tang, Bo-Sheng Ko, Hwei-Fang
More informationOne Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases
One Day BMT Course by Thai Society of Hematology Management of Graft Failure and Relapsed Diseases Piya Rujkijyanont, MD Division of Hematology-Oncology Department of Pediatrics Phramongkutklao Hospital
More informationEBMT2008_22_44:EBMT :29 Pagina 454 CHAPTER 30. HSCT for Hodgkin s lymphoma in adults. A. Sureda
EBMT2008_22_44:EBMT2008 6-11-2008 9:29 Pagina 454 * CHAPTER 30 HSCT for Hodgkin s lymphoma in adults A. Sureda EBMT2008_22_44:EBMT2008 6-11-2008 9:29 Pagina 455 CHAPTER 30 HL in adults 1. Introduction
More information3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25)
3 Results 3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25) Five infusions of monoclonal IL-2 receptor antibody (anti-cd25) were planned according to protocol between day 0 and day
More informationAllogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD
Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD Overview: Update on allogeneic transplantation for malignant and nonmalignant diseases: state
More informationKEY WORDS: Allogeneic, Hematopoietic cell transplantation, Graft-versus-host disease, Immunosuppressants, Cyclosporine, Tacrolimus
A Retrospective Comparison of Tacrolimus versus Cyclosporine with Methotrexate for Immunosuppression after Allogeneic Hematopoietic Cell Transplantation with Mobilized Blood Cells Yoshihiro Inamoto, 1
More informationAn Introduction to Bone Marrow Transplant
Introduction to Blood Cancers An Introduction to Bone Marrow Transplant Rushang Patel, MD, PhD, FACP Florida Hospital Medical Group S My RBC Plt Gran Polycythemia Vera Essential Thrombocythemia AML, CML,
More informationAcknowledgements. Department of Hematological Malignancy and Cellular Therapy, University of Kansas Medical Center
The Addition of Extracorporeal Photopheresis (ECP) to Tacrolimus and Methotrexate to Prevent Acute and Chronic Graft- Versus Host Disease in Myeloablative Hematopoietic Cell Transplant (HCT) Anthony Accurso,
More informationPoor Outcome in Steroid-Refractory Graft-Versus-Host Disease With Antithymocyte Globulin Treatment
Biology of Blood and Marrow Transplantation 8:155-160 (2002) 2002 American Society for Blood and Marrow Transplantation ASBMT Poor Outcome in Steroid-Refractory Graft-Versus-Host Disease With Antithymocyte
More informationAn Overview of Blood and Marrow Transplantation
An Overview of Blood and Marrow Transplantation October 24, 2009 Stephen Couban Department of Medicine Dalhousie University Objectives What are the types of blood and marrow transplantation? Who may benefit
More informationHaploidentical Transplantation today: and the alternatives
Haploidentical Transplantation today: and the alternatives Daniel Weisdorf MD University of Minnesota February, 2013 No matched sib: where to look? URD donor requires close HLA matching and 3-12 weeks
More informationFederica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani, 2 Rajni Agarwal-Hashmi, 3 Melissa Aldinger, 4 Franco Locatelli 1
Administration of Rivogenlecleucel (Rivo-cel, BPX-501) Following αβ T- and B-Cell Depleted Haplo-HSCT in Children With Transfusion-Dependent Thalassemia Federica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani,
More informationIntroduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018
Introduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018 The transfer of hematopoietic progenitor and stem cells for therapeutic purposes Hematopoietic Cell
More informationHaploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017
Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017 Allogeneic Transplant Recipients in the US, by Donor Type 9000
More informationTrends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014
Trends in Hematopoietic Cell Transplantation AAMAC Patient Education Day Oct 2014 Objectives Review the principles behind allogeneic stem cell transplantation Outline the process of transplant, some of
More informationCONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints
CONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH Potential
More informationRob Wynn RMCH & University of Manchester, UK. HCT in Children
Rob Wynn RMCH & University of Manchester, UK HCT in Children Summary Indications for HCT in children Donor selection for Paediatric HCT Using cords Achieving engraftment in HCT Conditioning Immune action
More informationRevista Cubana de Hematología, Inmunología y Hemoterapia. 2017; 36 (Suplemento).
Depletion of TCR alpha/beta+ T-lymphocytes from grafts for haplo haematopoietic CELL transplantation (HCT) in children Heilmann C, Ifversen M, Haastrup E, Fischer-Nielsen A. Haematopoietic Cell Transplantation
More informationHematology and Oncology, The Cleveland Clinic, Cleveland, Ohio; 3 Department of Biostatistics, The Ohio State University Hospitals, Columbus, Ohio
Biology of Blood and Marrow Transplantation 12:61-67 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1201-0004$32.00/0 doi:10.1016/j.bbmt.2005.06.004 High Disease Burden
More informationKEY WORDS: CRp, Platelet recovery, AML, MDS, Transplant
Platelet Recovery Before Allogeneic Stem Cell Transplantation Predicts Posttransplantation Outcomes in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome Gheath Alatrash, Matteo Pelosini,
More informationUKALL14. Non-Myeloablative Conditioning Regimen (1/1) Date started (dd/mm/yyyy) (Day 7) Weight (kg) BSA (m 2 )
Non-Myeloablative Conditioning Regimen (1/1) started (dd/mm/yyyy) (Day 7) BSA (m 2 ) Weight (kg) Please enter the daily dose given in the table below: Day Fludarabine (mg) Melphalan (mg) Alemtuzumab (mg)
More informationALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOBLASTIC LEUKEMIAS
ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOBLASTIC LEUKEMIAS Didier Blaise, MD Transplant and Cellular Therapy Unit (U2T) Department of Hematology Centre de Recherche en Cancérologie, Inserm U891
More informationThe National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient
1988 199 1992 1994 1996 1998 2 22 24 26 28 21 212 214 216 218 Adult Donors Cord Blood Units The National Donor Program Graft Sources for Hematopoietic Cell Transplantation Dennis L. Confer, MD Chief Medical
More informationBone Marrow Transplantation in Myelodysplastic Syndromes. An overview for the Myelodysplasia Support Group of Ottawa
Bone Marrow Transplantation in Myelodysplastic Syndromes An overview for the Myelodysplasia Support Group of Ottawa Objectives Provide brief review of marrow failure Re emphasize the importance of predictions
More informationWhat s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016
What s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016 Division of Hematology-Oncology University of Pennsylvania Perelman School of Medicine 1 Who should be transplanted and how? Updates
More informationMUD SCT for Paediatric AML?
7 th South African Symposium on Haematopoietic Stem Cell Transplantation MUD SCT for Paediatric AML? Alan Davidson Haematology / Oncology Service Red Cross Children s Hospital THE SCENARIO A 10 year old
More informationStem Cell Transplantation for Severe Aplastic Anemia
Number of Transplants 10/24/2011 Stem Cell Transplantation for Severe Aplastic Anemia Claudio Anasetti, MD Professor of Oncology and Medicine Chair, Blood and Marrow Transplant Dpt Moffitt Cancer Center
More informationExperience of patients transplanted with naïve T cell depleted stem cell graft in CMUH
Experience of patients transplanted with naïve T cell depleted stem cell graft in CMUH Tzu-Ting Chen, Wen-Jyi Lo, Chiao-Lin Lin, Ching-Chan Lin, Li-Yuan Bai, Supeng Yeh, Chang-Fang Chiu Hematology and
More informationBone Marrow Transplantation and the Potential Role of Iomab-B
Bone Marrow Transplantation and the Potential Role of Iomab-B Hillard M. Lazarus, MD, FACP Professor of Medicine, Director of Novel Cell Therapy Case Western Reserve University 1 Hematopoietic Cell Transplantation
More informationMUD SCT. Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University
MUD SCT Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outlines Optimal match criteria for unrelated adult donors Role of ATG in MUD-SCT Post-transplant
More informationHematopoietic Stem Cell Transplantation for Patients with Chronic Myeloid Leukemia
398 Hematopoietic Stem Cell Transplantation for Patients with Chronic Myeloid Leukemia Qifa Uu Zhiping Fan Jing Sun Yu Zhang Xiaoli Uu Dan Xu Bing Xu Ru Feng Fanyi Meng Shuyun Zhou Department of Hematology,
More informationTherapeutic Advances in Treatment of Aplastic Anemia. Seiji Kojima MD. PhD.
Therapeutic Advances in Treatment of Aplastic Anemia Seiji Kojima MD. PhD. Department of Pediatrics Nagoya University Graduate School of Medicine Chairman of the Severe Aplastic Anemia Working Party Asia-Pacific
More informationHaplo vs Cord vs URD Debate
3rd Annual ASBMT Regional Conference for NPs, PAs and Fellows Haplo vs Cord vs URD Debate Claudio G. Brunstein Associate Professor University of Minnesota Medical School Take home message Finding a donor
More informationDisclosure. Objectives 1/22/2015
Evaluation of the Impact of Anti Thymocyte Globulin (ATG) on Post Hematopoietic Stem Cell Transplant (HCT) Outcomes in Patients Undergoing Allogeneic HCT Katie S. Kaminski, PharmD, CPP University of North
More informationAutologous versus Allogeneic Unrelated Donor Transplantation for Acute Lymphoblastic Leukemia: Comparative Toxicity and Outcomes
Biology of Blood and Marrow Transplantation 8:213-220 (2002) 2002 American Society for Blood and Marrow Transplantation ASBMT Autologous versus Allogeneic Unrelated Donor Transplantation for Acute Lymphoblastic
More informationMyeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris
Myeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris 18th ESH - EBMT Training Course on HSCT 8-10 May 2014, Vienna,
More informationLong-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single Center Retrospective Analysis
Pathol. Oncol. Res. (2018) 24:469 475 DOI 10.1007/s12253-017-0266-7 ORIGINAL ARTICLE Long-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single
More informationAutologous bone marrow transplantation for patients with acute myeloid leukaemia: prospective follow-up study
Bone marrow transplantation Autologous bone marrow transplantation for patients with acute myeloid leukaemia: prospective follow-up study YK Mak, CH Chan, YC Chu, YT Chen, CK Lau, JSM Lau Objective. To
More informationAcute GVHD. ESH-EBMT 2009 Latimer A. Devergie
Acute GVHD ESH-EBMT 2009 Latimer A. Devergie Acute GVHD Activated Donor T cells damage host epithelial cells after an inflammatory cascade that begins after the preparative regimen GVHD is the major barrier
More informationClinical Policy: Donor Lymphocyte Infusion
Clinical Policy: Reference Number: PA.CP.MP.101 Effective Date: 01/18 Last Review Date: 11/16 Coding Implications Revision Log This policy describes the medical necessity requirements for a donor lymphocyte
More informationFeasibility and Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in 30 Patients with Poor Risk Acute Myeloid Leukemia Older than 60 Years
The Open Leukemia Journal, 2010, 3, 55-59 55 Open Access Feasibility and Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in 30 Patients with Poor Risk Acute Myeloid Leukemia Older than Years
More informationHee-Je Kim, Woo-Sung Min, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Chang-Ki Min, Seok Lee, Seok-Goo Cho, Jong-Youl Jin, Jong-Wook Lee, Chun-Choo Kim
Successful Prevention of Acute Graft-versus-Host Disease Using Low-Dose Antithymocyte Globulin after Mismatched, Unrelated, Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia Hee-Je
More informationInduction Therapy & Stem Cell Transplantation for Myeloma
Induction Therapy & Stem Cell Transplantation for Myeloma William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director, Autologous Stem Cell Transplant
More informationAlloreattività e Tolleranza nei Trapianti di Cellule Staminali Emopoietiche Allogeniche
Alloreattività e Tolleranza nei Trapianti di Cellule Staminali Emopoietiche Allogeniche Massimo Fabrizio Martelli Ematologia ed Immunologia Clinica Università degli Studi di Perugia 41 Congresso Nazionale
More informationManipulation of T Cells in the Thnsplant Inoculum
International Journal of Cell Cloning 4: 122-126 Suppl 1 (1986) Manipulation of T Cells in the Thnsplant Inoculum J. Kersey Bone Marrow Transplantation Program, University of Minnesota, Minneapolis, MN,
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Acute Myeloid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplant_for_acute_myeloid_leukemia
More informationHSCT - Minimum Essential Data - A FOLLOW UP REPORT - ANNUAL
CIC: HSCT - Minimum Essential Data - A FOLLOW UP REPORT - ANNUAL Disease PRIMARY DISEASE DIAGNOSIS Centre Identification EBMT Code (CIC): Hospital: Contact person: Unit: Email: Patient Data Date of this
More informationIntroduction to Hematopoietic Stem Cell Transplantation
Faculty Disclosures Introduction to Hematopoietic Stem Cell Transplantation Nothing to disclose Jeanne McCarthy-Kaiser, PharmD, BCOP Clinical Pharmacist, Autologous Stem Cell Transplant/Long- Term Follow-Up
More informationHematopoietic Stem Cells, Stem Cell Processing, and Transplantation
Hematopoietic Stem Cells, Stem Cell Processing, and Joseph (Yossi) Schwartz, M irector, Hemotherapy and Stem Cell Processing Facility Bone Marrow Can Cure: Leukemia Lymphoma Multiple Myeloma Genetic iseases:
More informationBB&MT. KEY WORDS Acute lymphoblastic leukemia Hematopoietic stem cell transplantation Therapy Adult
Biology of Blood and Marrow Transplantation 12:1-30 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1201-0001$32.00/0 doi:10.1016/j.bbmt.2005.10.018 The Role of Cytotoxic
More informationDonor lymphocyte infusion Prophylactic T cell infusion after T cell-depleted bone marrow transplantation in patients with refractory lymphoma
(2002) 29, 65 620 2002 Nature Publishing Group All rights reserved 0268 3369/02 $25.00 www.nature.com/bmt Donor lymphocyte infusion Prophylactic T cell infusion after T cell-depleted bone marrow transplantation
More informationDonatore HLA identico di anni o MUD giovane?
Donatore HLA identico di 60-70 anni o MUD giovane? Stella Santarone Dipartimento di Ematologia, Medicina Trasfusionale e Biotecnologie Pescara AGENDA 1. Stem Cell Donation: fatalities and severe events
More informationTransition from active to palliative care EBMT, Geneva, Dr. med. Gayathri Nair Division of Hematology
Transition from active to palliative care EBMT, Geneva, 03.04.2012 Dr. med. Gayathri Nair Division of Hematology 3 cases of patients who underwent an allogeneic stem cell transplantation in curative intent
More informationDonor Lymphocyte Infusion for Malignancies Treated with an Allogeneic Hematopoietic Stem-Cell Transplant
Last Review Status/Date: September 2014 Page: 1 of 8 Malignancies Treated with an Allogeneic Description Donor lymphocyte infusion (DLI), also called donor leukocyte or buffy-coat infusion is a type of
More informationA CLINICAL STUDY OF THE HEMATOPOIETIC STEM CELL TRANSPLANTATION IN 112 PATIENTS WITH LEUKEMIA AND OTHER MALIGNANT DISEASES
Chinese Journal of Cancer Research 9(1):36--40,1997, Clinical Observations A CLINICAL STUDY OF THE HEMATOPOIETIC STEM CELL TRANSPLANTATION IN 112 PATIENTS WITH LEUKEMIA AND OTHER MALIGNANT DISEASES Liu
More informationThe question is not whether or not to deplete T-cells, but how to deplete which T-cells
The question is not whether or not to deplete T-cells, but how to deplete which T-cells CD34+ positive selection Negative Depletion of: CD3/CD19 TcRαβ/CD19 T-cell depletion: positive selection versus negative
More informationCurrent Status of Haploidentical Hematopoietic Stem Cell Transplantation
Current Status of Haploidentical Hematopoietic Stem Cell Transplantation Annalisa Ruggeri, MD, PhD Hematology and BMT Unit Hôpital Saint Antoine, Paris, France #EBMTITC16 www.ebmt.org Hematopoietic SCT
More informationA.M.W. van Marion. H.M. Lokhorst. N.W.C.J. van de Donk. J.G. van den Tweel. Histopathology 2002, 41 (suppl 2):77-92 (modified)
chapter 4 The significance of monoclonal plasma cells in the bone marrow biopsies of patients with multiple myeloma following allogeneic or autologous stem cell transplantation A.M.W. van Marion H.M. Lokhorst
More informationCase-Control Study: ABO-Incompatible Plasma Causing Hepatic Veno-Occlusive Disease in HSCT
Case-Control Study: ABO-Incompatible Plasma Causing Hepatic Veno-Occlusive Disease in HSCT Erin Meyer, DO, MPH Assistant Medical Director of Blood, Tissue, and Apheresis Services Children s Healthcare
More informationClinical Policy Bulletin: Hematopoietic Cell Transplantation for Selected Leukemias
Go Clinical Policy Bulletin: Hematopoietic Cell Transplantation for Selected Leukemias Number: 0640 Policy *Please see amendment for Pennsylvania Medicaid at the end of this CPB. Additional Information
More informationHaploidentical Transplants for Lymphoma. Andrea Bacigalupo Universita Cattolica Policlinico Gemelli Roma - Italy
Haploidentical Transplants for Lymphoma Andrea Bacigalupo Universita Cattolica Policlinico Gemelli Roma - Italy HODGKIN NON HODGKIN Non Myelo Ablative Regimen Luznik L et al BBMT 2008 Comparison of Outcomes
More informationDoes anti-thymocyte globulin have a place in busulfan/fludarabine
ORIGINAL ARTICLE Korean J Intern Med 2016;31:750-761 Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation? Young
More informationDedicated to Gordon. Stem Cell Transplantation: The Journey
Dedicated to Gordon Stem Cell Transplantation: The Journey 1949 Jacobson et al: Radioprotection by lead shielding of the spleen of a lethally irradiated animal 1951 Lorenz et al: Radiation protection
More informationSickle Cell Diseasechronic. curable disease? Objectives. Why would a family ask about cure for SCD?
Sickle Cell Diseasechronic illness or curable disease? Gregory M.T. Guilcher MD, FRCPC, FAAP Objectives To review the general principles of hematopoietic stem cell transplantation (HSCT), including risks
More informationHigh-Dose Carmustine, Etoposide, and Cyclophosphamide Followed by Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma
Biology of Blood and Marrow Transplantation 12:703-711 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1207-0002$32.00/0 doi:10.1016/j.bbmt.2006.02.009 High-Dose Carmustine,
More informationKEY WORDS: Unrelated SCT, HLA-mismatch, ATG, Graft-versus-host disease
HLA-Mismatched Unrelated Donors as an Alternative Graft Source for Allogeneic Stem Cell Transplantation after Antithymocyte Globulin-Containing Conditioning Regimen Nicolaus Kröger, 1 Tatjana Zabelina,
More informationExperimental Hematology 31 (2003)
Experimental Hematology 31 (2003) 1182 1186 Busulfan-cyclophosphamide versus total body irradiation cyclophosphamide as preparative regimen before allogeneic hematopoietic stem cell transplantation for
More informationHematopoietic Cell Transplantation for Myelofibrosis. Outline
Hematopoietic Cell Transplantation for Myelofibrosis H.Joachim Deeg MD Fred Hutchinson Cancer Research Center & University of Washington, Seattle WA Great Debates, NY, 4/28/2012 Outline Rationale for hematopoietic
More information& 2007 Nature Publishing Group All rights reserved /07 $
(7), 437 441 & 7 Nature Publishing Group All rights reserved 268-3369/7 $. www.nature.com/bmt ORIGINAL ARTICLE Patients mobilizing large numbers of CD34 þ cells ( super mobilizers ) have improved survival
More informationBack to the Future: The Resurgence of Bone Marrow??
Back to the Future: The Resurgence of Bone Marrow?? Thomas Spitzer, MD Director. Bone Marrow Transplant Program Massachusetts General Hospital Professor of Medicine, Harvard Medical School Bone Marrow
More informationMedical Policy. MP Hematopoietic Cell Transplantation for Acute Myeloid Leukemia
Medical Policy MP 8.01.26 BCBSA Ref. Policy: 8.01.26 Last Review: 01/30/2018 Effective Date: 01/30/2018 Section: Therapy Related Policies 2.04.124 Genetic Testing for FLT3, NPM1, and CEBPA Variants in
More informationOutcome of acute leukemia patients with central nervous system (CNS) involvement treated with total body or CNS irradiation before transplantation
Original Article Page 1 of 9 Outcome of acute leukemia patients with central nervous system (CNS) involvement treated with total body or CNS irradiation before transplantation Wen-Han Kuo 1, Yu-Hsuan Chen
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_cell_transplantation_for_cll_and_sll 2/2001
More informationThe future of HSCT. John Barrett, MD, NHBLI, NIH Bethesda MD
The future of HSCT John Barrett, MD, NHBLI, NIH Bethesda MD Transplants today Current approaches to improve SCT outcome Optimize stem cell dose and source BMT? PBSCT? Adjusting post transplant I/S to minimize
More informationM Cavo, G Bandini, M Benni, A Gozzetti, S Ronconi, G Rosti, E Zamagni, RM Lemoli, A Bonini, A Belardinelli, MR Motta, S Rizzi and S Tura
Bone Marrow Transplantation, (1998) 22, 27 32 1998 Stockton Press All rights reserved 268 3369/98 $12. http://www.stockton-press.co.uk/bmt High-dose busulfan and cyclophosphamide are an effective conditioning
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/2296
More informationASBMT and Marrow Transplantation
Biol Blood Marrow Transplant 19 (2013) 661e675 Brief Articles Improved Survival over the Last Decade in Pediatric Patients Requiring Dialysis after Hematopoietic Cell Transplantation American Society for
More informationNeutrophil Recovery: The. Posttransplant Recovery. Bus11_1.ppt
Neutrophil Recovery: The First Step in Posttransplant Recovery No conflicts of interest to disclose Bus11_1.ppt Blood is Made in the Bone Marrow Blood Stem Cell Pre-B White cells B Lymphocyte T Lymphocyte
More informationHaploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia
Haploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia Carmem Bonfim Director Pediatric Blood and Marrow Transplantation Program HC Federal
More informationNon-Myeloablative Transplantation
Non-Myeloablative Transplantation David G. Maloney, Brenda M. Sandmaier, Stephen Mackinnon, and Judith A. Shizuru The concept of utilizing enhanced immunosuppression rather than myeloablative cytotoxic
More informationDisclosures. Franco Locatelli Advisory Board, Bellicum Pharmaceuticals, Inc. Lakshmanan Krishnamurti No disclosures. David Jacobsohn.
Administration of Rivogenlecleucel (rivo-cel; BPX-51) Cells Following αβ-t and B-cell-Depleted HLA Haploidentical HSCT (haplo-hsct) in Children With Acute Leukemias Franco Locatelli, 1 Annalisa Ruggeri,
More informationAcute myeloid leukemia: prognosis and treatment. Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg
Acute myeloid leukemia: prognosis and treatment Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg Patient Female, 39 years History: hypothyroidism Present:
More informationShall young patients with severe aplastic anemia without donors receive BMT from alternative source of HCT? Elias Hallack Atta, MD, PhD
Shall young patients with severe aplastic anemia without donors receive BMT from alternative source of HCT? Elias Hallack Atta, MD, PhD Declaração de Conflito de Interesse Declaro que possuo conflito de
More informationCauses of Death. J. Douglas Rizzo, MD MS February, New11_1.ppt
Causes of Death J. Douglas Rizzo, MD MS February, 2012 New11_1.ppt Overview Attribution of COD important for research purposes Frequently not correctly coded or completely reported Source of confusion
More informationClinical Use of Umbilical Cord Blood Hematopoietic Stem Cells
Biology of Blood and Marrow Transplantation 12:34-41 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1201-0107$32.00/0 doi:10.1016/j.bbmt.2005.09.006 Clinical Use of Umbilical
More informationUPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma
UPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma Supported by a grant from Supported by a grant from UPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma Jonathan W.
More informationReduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation for LLM: Hype, Reality or Time for a Rethink
Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation for LLM: Hype, Reality or Time for a Rethink Avichi Shimoni, Arnon Nagler Hematology Division and BMT, Chaim Sheba Medical Center,
More informationTransplantation with unrelated bone marrow in leukaemic patients above 40 years of age
Bone Marrow Transplantation, (1998) 21, 43 49 1998 Stockton Press All rights reserved 0268 3369/98 $12.00 Transplantation with unrelated bone marrow in leukaemic patients above 40 years of age O Ringdén
More informationUmbilical Cord Blood Transplantation
Umbilical Cord Blood Transplantation Current Results John E. Wagner, M.D. Blood and Marrow Transplant Program and Stem Cell Institute University of Minnesota Donor Choices Unrelated Marrow/PBSC Results
More informationTHE ROLE OF TBI IN STEM CELL TRANSPLANTATION. Dr. Biju George Professor Department of Haematology CMC Vellore
THE ROLE OF TBI IN STEM CELL TRANSPLANTATION Dr. Biju George Professor Department of Haematology CMC Vellore Introduction Radiotherapy is the medical use of ionising radiation. TBI or Total Body Irradiation
More informationAppendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand
Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand This list provides indications for the majority of adult BMTs that are performed in New Zealand. A small number of BMTs
More informationLow-Dose Total Body Irradiation, Fludarabine, and Antithymocyte Globulin Conditioning for Nonmyeloablative Allogeneic Transplantation
Biology of Blood and Marrow Transplantation 9:453-459 (2003) 2003 American Society for Blood and Marrow Transplantation 1083-8791/03/0907-0005$30.00/0 doi:10.1016/s1083-8791(03)00139-3 Low-Dose Total Body
More informationCell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. Company Presentation June 2016
Cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders Company Presentation June 2016 Disclaimer These slides and the accompanying oral presentation contain
More information